Drawing for MATRIDERM

USPTO serial 75796470

MATRIDERM

Reviewed by CopyMark Law Group

Reg. 2847096Status 711
Filing date
Status date
Registration date
Jun 1, 2004
Examiner
CARROLL, DORITT
Law office
POST REGISTRATION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with MATRIDERM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

ANDREW MCLEAN

ANDREW MCLEAN PENTHOUSE, WASHINGTON MALLSTRAKAN INTERNATIONAL LIMITED1 CHURCH ST, HAMILTON HM11

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for wound care management, infection control, pain relief, skin, bone and diseases of the central nervous systemSECTION 7(e) - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 24, 2005C7..CANCELLED SECTION 7-TOTAL—
Mar 28, 2005C7RFREQUEST FOR SECT 7 TOTAL SURRENDER FILED—
Mar 28, 2005MAILPAPER RECEIVED—
Jun 1, 2004R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 9, 2004PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 18, 2004NPUBNOTICE OF PUBLICATION—
Oct 28, 2003DOCKASSIGNED TO EXAMINER—
Oct 21, 2003PCGRPETITION TO DIRECTOR GRANTED—
Aug 20, 200344EASEC. 44(E) CLAIM ADDED—
Aug 20, 20031.BDSec. 1(B) CLAIM DELETED—
Aug 20, 2003IUCNNOTICE OF ALLOWANCE CANCELLED—
Aug 20, 2003PCRCPETITION TO DIRECTOR RECEIVED—
Aug 20, 2003MAILPAPER RECEIVED—
Aug 19, 2003MAILPAPER RECEIVED—
Aug 14, 2003EX4GSOU EXTENSION 4 GRANTED—
Aug 14, 2003EXT4SOU EXTENSION 4 FILED—
Apr 21, 2003EX3GSOU EXTENSION 3 GRANTED—
Feb 3, 2003EXT3SOU EXTENSION 3 FILED—
Feb 3, 2003MAILPAPER RECEIVED—
Aug 27, 2002EX2GSOU EXTENSION 2 GRANTED—
Aug 1, 2002EXT2SOU EXTENSION 2 FILED—
Aug 1, 2002MAILPAPER RECEIVED—
Feb 6, 2002EX1GSOU EXTENSION 1 GRANTED—
Feb 6, 2002EXT1SOU EXTENSION 1 FILED—
Aug 14, 2001NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 22, 2001PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 9, 2001NPUBNOTICE OF PUBLICATION—
Sep 21, 2000CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 6, 2000CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 6, 2000CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 29, 1999DOCKASSIGNED TO EXAMINER—
Dec 27, 1999DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance